7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
WALTHAM, Mass., Feb. 04, 2016 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it will report unaudited consolidated financial results for the fourth quarter and year ended December 31, 2015 before the U.S. financial markets open on Wednesday, February 17, 2016. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET, during which management will present an update on recent developments and discuss the company’s fourth quarter and full year 2015 financial and operating results.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on February 17, 2016 through midnight on February 24, 2016. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 44838187.
The call will be webcast with slides and accessible through the Investors section of the company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on February 17, 2016 through midnight on March 18, 2016.
About AMAG
AMAG Pharmaceuticals uses its business and clinical expertise to develop and commercialize products that provide clear benefits and improve people’s lives. Based in Waltham, MA, AMAG has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. AMAG continues to work to expand the impact of these and future products for patients by delivering on its growth strategy, which includes organic growth, as well as the pursuit of products and companies that align with AMAG’s existing therapeutic areas or those that could benefit from its proven core competencies. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals Contact: Maryann Cimino Manager, Corporate Communications & External Affairs 617-498-3375
